Drug Profile
E 0474
Latest Information Update: 01 Jul 2003
Price :
$50
*
At a glance
- Originator Ebewe
- Class Benzofurans; Class III antiarrhythmics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
- 09 Jul 1998 New profile
- 09 Jul 1998 Preclinical development for Arrhythmias in Austria (Unknown route)